Lenvatinib和Atezolizumab联合治疗合并肝细胞-胆管癌的疗效。

IF 1.6 4区医学 Q4 ONCOLOGY

Anticancer research Pub Date : 2025-03-01 DOI:10.21873/anticanres.17499

Norikazu Tanabe, Issei Saeki, Kenji Yamaoka, Tomokazu Kawaoka, Tetsu Tomonari, Joji Tani, Takeshi Terashima, Yusuke Kawamura, Shiro Oka, Tetsuji Takayama, Hideki Kobara, Taro Yamashita, Norio Akuta, Takahiro Yamasaki, Taro Takami

{"title":"Lenvatinib和Atezolizumab联合治疗合并肝细胞-胆管癌的疗效。","authors":"Norikazu Tanabe, Issei Saeki, Kenji Yamaoka, Tomokazu Kawaoka, Tetsu Tomonari, Joji Tani, Takeshi Terashima, Yusuke Kawamura, Shiro Oka, Tetsuji Takayama, Hideki Kobara, Taro Yamashita, Norio Akuta, Takahiro Yamasaki, Taro Takami","doi":"10.21873/anticanres.17499","DOIUrl":null,"url":null,"abstract":"Background/aim: Surgical resection remains the only curative treatment for combined hepatocellular-cholangiocarcinoma; however, systemic therapy is the primary treatment option for unresectable cases. This multicenter retrospective study aimed to assess the efficacy of systemic therapy for unresectable combined hepatocellular-cholangiocarcinoma.Patients and methods: Twenty-one patients with histologically confirmed or clinically diagnosed combined hepatocellular-cholangiocarcinoma who received systemic therapy were included. First-line regimens consisted of lenvatinib (n=14) and atezolizumab plus bevacizumab (n=7) and their therapeutic efficacy was evaluated.Results: The objective response and disease control rates were 42.9% and 92.9% for lenvatinib, and 14.3% and 100% for atezolizumab plus bevacizumab, respectively. Median overall survival for all treatments was 14.9 months and median progression-free survival was 6.5 months. By regimen, median overall and progression-free survival was 14.9 and 6.1 months for lenvatinib, and \"not reached\" and 7.9 months for atezolizumab plus bevacizumab, respectively.Conclusion: Lenvatinib and atezolizumab plus bevacizumab exhibited potential activity in patients with combined hepatocellular-cholangiocarcinoma.","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"45 3","pages":"1117-1125"},"PeriodicalIF":1.6000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Efficacy of Lenvatinib and Atezolizumab Bevacizumab Combination Therapy in Patients With Combined Hepatocellular-cholangiocarcinoma.\",\"authors\":\"Norikazu Tanabe, Issei Saeki, Kenji Yamaoka, Tomokazu Kawaoka, Tetsu Tomonari, Joji Tani, Takeshi Terashima, Yusuke Kawamura, Shiro Oka, Tetsuji Takayama, Hideki Kobara, Taro Yamashita, Norio Akuta, Takahiro Yamasaki, Taro Takami\",\"doi\":\"10.21873/anticanres.17499\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background/aim: Surgical resection remains the only curative treatment for combined hepatocellular-cholangiocarcinoma; however, systemic therapy is the primary treatment option for unresectable cases. This multicenter retrospective study aimed to assess the efficacy of systemic therapy for unresectable combined hepatocellular-cholangiocarcinoma.Patients and methods: Twenty-one patients with histologically confirmed or clinically diagnosed combined hepatocellular-cholangiocarcinoma who received systemic therapy were included. First-line regimens consisted of lenvatinib (n=14) and atezolizumab plus bevacizumab (n=7) and their therapeutic efficacy was evaluated.Results: The objective response and disease control rates were 42.9% and 92.9% for lenvatinib, and 14.3% and 100% for atezolizumab plus bevacizumab, respectively. Median overall survival for all treatments was 14.9 months and median progression-free survival was 6.5 months. By regimen, median overall and progression-free survival was 14.9 and 6.1 months for lenvatinib, and \\\"not reached\\\" and 7.9 months for atezolizumab plus bevacizumab, respectively.Conclusion: Lenvatinib and atezolizumab plus bevacizumab exhibited potential activity in patients with combined hepatocellular-cholangiocarcinoma.\",\"PeriodicalId\":8072,\"journal\":{\"name\":\"Anticancer research\",\"volume\":\"45 3\",\"pages\":\"1117-1125\"},\"PeriodicalIF\":1.6000,\"publicationDate\":\"2025-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Anticancer research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.21873/anticanres.17499\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anticancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21873/anticanres.17499","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

背景/目的：手术切除仍然是治疗肝细胞胆管合并癌的唯一方法；然而，对于不能切除的病例，全身治疗是主要的治疗选择。本多中心回顾性研究旨在评估全身治疗不可切除的肝细胞胆管合并癌的疗效。患者和方法：纳入21例经组织学证实或临床诊断为肝细胞胆管合并癌并接受全身治疗的患者。一线方案由lenvatinib （n=14）和atezolizumab + bevacizumab （n=7）组成，并评估其治疗效果。结果：lenvatinib组的客观有效率为42.9%，疾病控制率为92.9%，atezolizumab + bevacizumab组的客观有效率为14.3%，疾病控制率为100%。所有治疗的中位总生存期为14.9个月，中位无进展生存期为6.5个月。根据方案，lenvatinib的中位总生存期和无进展生存期分别为14.9个月和6.1个月，atezolizumab + bevacizumab的中位总生存期和无进展生存期分别为“未达到”和7.9个月。结论：Lenvatinib和atezolizumab + bevacizumab对合并肝细胞-胆管癌患者具有潜在的活性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Efficacy of Lenvatinib and Atezolizumab Bevacizumab Combination Therapy in Patients With Combined Hepatocellular-cholangiocarcinoma.

Background/aim: Surgical resection remains the only curative treatment for combined hepatocellular-cholangiocarcinoma; however, systemic therapy is the primary treatment option for unresectable cases. This multicenter retrospective study aimed to assess the efficacy of systemic therapy for unresectable combined hepatocellular-cholangiocarcinoma.

Patients and methods: Twenty-one patients with histologically confirmed or clinically diagnosed combined hepatocellular-cholangiocarcinoma who received systemic therapy were included. First-line regimens consisted of lenvatinib (n=14) and atezolizumab plus bevacizumab (n=7) and their therapeutic efficacy was evaluated.

Results: The objective response and disease control rates were 42.9% and 92.9% for lenvatinib, and 14.3% and 100% for atezolizumab plus bevacizumab, respectively. Median overall survival for all treatments was 14.9 months and median progression-free survival was 6.5 months. By regimen, median overall and progression-free survival was 14.9 and 6.1 months for lenvatinib, and "not reached" and 7.9 months for atezolizumab plus bevacizumab, respectively.

Conclusion: Lenvatinib and atezolizumab plus bevacizumab exhibited potential activity in patients with combined hepatocellular-cholangiocarcinoma.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Anticancer research 医学-肿瘤学

CiteScore

3.70

自引率

10.00%

发文量

566

审稿时长

2 months

期刊介绍： ANTICANCER RESEARCH is an independent international peer-reviewed journal devoted to the rapid publication of high quality original articles and reviews on all aspects of experimental and clinical oncology. Prompt evaluation of all submitted articles in confidence and rapid publication within 1-2 months of acceptance are guaranteed. ANTICANCER RESEARCH was established in 1981 and is published monthly (bimonthly until the end of 2008). Each annual volume contains twelve issues and index. Each issue may be divided into three parts (A: Reviews, B: Experimental studies, and C: Clinical and Epidemiological studies). Special issues, presenting the proceedings of meetings or groups of papers on topics of significant progress, will also be included in each volume. There is no limitation to the number of pages per issue.